New York State Teachers Retirement System Sells 2,694 Shares of Artivion, Inc. (NYSE:AORT)

New York State Teachers Retirement System lessened its holdings in Artivion, Inc. (NYSE:AORT) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,472 shares of the company’s stock after selling 2,694 shares during the quarter. New York State Teachers Retirement System’s holdings in Artivion were worth $1,349,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in AORT. Tower Research Capital LLC TRC boosted its position in shares of Artivion by 89.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,677 shares of the company’s stock valued at $29,000 after acquiring an additional 791 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Artivion by 7.8% during the fourth quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock valued at $239,000 after purchasing an additional 968 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Artivion by 6.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,628 shares of the company’s stock valued at $267,000 after purchasing an additional 1,133 shares during the period. Advisor Group Holdings Inc. raised its holdings in shares of Artivion by 54.0% in the 4th quarter. Advisor Group Holdings Inc. now owns 3,859 shares of the company’s stock worth $47,000 after buying an additional 1,353 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Artivion by 7.3% during the 4th quarter. JPMorgan Chase & Co. now owns 25,958 shares of the company’s stock worth $315,000 after buying an additional 1,773 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Stock Performance

NYSE:AORT opened at $19.99 on Thursday. The stock has a market capitalization of $823.59 million, a P/E ratio of -26.65 and a beta of 1.67. Artivion, Inc. has a 1 year low of $12.16 and a 1 year high of $21.90. The firm has a 50 day moving average of $19.81 and a 200-day moving average of $17.46. The company has a current ratio of 4.85, a quick ratio of 3.43 and a debt-to-equity ratio of 1.10.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, February 15th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.24. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. The firm had revenue of $93.67 million during the quarter, compared to the consensus estimate of $89.75 million. As a group, sell-side analysts anticipate that Artivion, Inc. will post 0.26 EPS for the current fiscal year.

Analyst Ratings Changes

AORT has been the topic of a number of analyst reports. Stifel Nicolaus upped their price target on Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 target price on shares of Artivion in a report on Monday, April 8th.

Insider Buying and Selling at Artivion

In other Artivion news, CEO James P. Mackin sold 72,069 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $18.85, for a total value of $1,358,500.65. Following the completion of the transaction, the chief executive officer now directly owns 539,036 shares of the company’s stock, valued at $10,160,828.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO James P. Mackin sold 72,069 shares of Artivion stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $18.85, for a total value of $1,358,500.65. Following the completion of the sale, the chief executive officer now directly owns 539,036 shares of the company’s stock, valued at approximately $10,160,828.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Amy Horton sold 1,695 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total value of $31,967.70. Following the transaction, the chief accounting officer now directly owns 122,345 shares in the company, valued at approximately $2,307,426.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 149,952 shares of company stock worth $2,891,627. 8.10% of the stock is currently owned by corporate insiders.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.